Morgan Stanley assumed coverage of Immunocore (IMCR) with an Equal Weight rating and $35 price target The firm remains positive on Kimmtrak sales, but believes sales expectations are largely reflected in the shares, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore Holdings: Pioneering HIV Cure with Promising Phase 1 STRIVE Trial Results
- Immunocore Reports 2024 Growth and Strategic Advances
- Immunocore’s Strategic Expansion and Robust Pipeline Drive Buy Rating
- Immunocore Holdings: Positive Earnings Call Highlights Growth
- Immunocore price target lowered to $85 from $88 at Oppenheimer
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue